BioXL is a biopharma company focused on developing innovative solutions for critical and underserved medical conditions. Our pivotal portfolio projects include: CancerPredict: a diagnostic test, based on biomarker, aims to predict breast cancer development. The test planned to be integrated in the current screening program, and will be carried out by authorized labs. Product includes proprietary testing kit and AI-powered software. The project received grant from IIA (Israel Innovation Authority) CeaseCancer,: an anti-cancer biologic drug for Pancreatic cancer treatment. The product is an injectable (i.v or S.C) where the drug substance (API) is a human-recombinant version of a naturally expressed regulatory protein, having tumor suppression activity in the human body. The API has a unique MoA, affecting only cancer cells and does not harm normal cells. Efficacy and safety demonstrated in vitro and in animal models. Synergy was demonstrated with chemotherapy. The intended treatment is monotherapy or in combination with other treatments (i.e chemo or radiation)., as first line treatment or second line, where other therapies are not effective, i.e, in cases of cancer recurrence, resistant to chemotherapy. NES Pharma: drug treatment to prevent or slow dementia progression. The drug combines drug substances targeting glutamate excitotoxicity, with different MoAs, enabling efficacy with minimal adverse effects. The drug intended for subscription to people diagnosed at MCI (Mild Cognitive Impairment) or people at high risk to develop dementia. Other projects: AMP-Bio (antimicrobial drug to treat multi-drug resistant pathogens) and Marathon (delivery for use in MRT (Mitochondrial Replacement therapy))